Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2426-2434

  Gore, M E ^a   Mainwaring, P ^a   A'Hern, R ^a   MacFarlane, V ^a   Slevin, M ^a   Harper, P ^a   Osborne, R ^a   Mansi, J ^a   Blake, P ^a   Wiltshaw, E ^a   Shepherd, J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 7144228608     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2426     Document Type: Article

References (41)

1. Gruppo Intergionale Cooperative Oncologico Ginecologia: Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987
2. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 303:884-893, 1991
3. Allen DG, Baak J, Belpomme D, et al: Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 4:S83-S88, 1993(suppl 4)
4. Torri V: Randomised study of cyclophosphamide, doxorubicin and cisplatin (CAP) vs single agent carboplatin in ovarian cancer patients requiring chemotherapy: Interim results of ICON2. Proc Am Soc Clin Oncol 15:752, 1996 (abstr)
5. A'Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13:726-732, 1995
6. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian cancer. J Clin Oncol 9:1668-1674, 1991
7. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
8. Parmar MKB, Sandercock J: Chemotherapy for ovarian cancer. N Engl J Med 334:1268-1269, 1996 (letter)
9. Lacave AJ, Pelaez I, Palcis I: Chemotherapy for ovarian cancer. N Engl J Med 334:1269-1270, 1996 (letter)
10. Piccart MJ, Bertelsen K, Stuart G, et al: Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NC1-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 16:1258, 1997 (abstr)
11. Ozols RF, Behrens BC, Ostchega Y, et al: High dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 12:59-65, 1985 (suppl A)
12. Behrens BC, Hamilton TC, Masuda H, et al: Characteristics of cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and the evaluation of platinum analogues. Cancer Res 47:414-418, 1987
13. Levin L, Hryniuk WN: Dose-intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol 5:756-767, 1987
14. Enrlick CE, Einhorn L, Stehman FB, et al: Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan - The Indiana University Experience. Clin Obst Gynaecol 10:325-335, 1983
15. Ngan HYS, Choo YC, Cheung M, et al: A randomised study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35:221-227, 1989
16. Colombo N, Pittelli MR, Parma G: Cisplatin (P) dose-intensity in advanced ovarian cancer (AOC): A randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Am Soc Clin Oncol 12:255, 1993 (abstr)
17. Murphy D, Crowther D, Renninson J, et al: A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 4:377-383, 1993
18. Bella M, Cocconi G, Lotticci R, et al: Mature results of a prospective randomised trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann Oncol 5:23, 1994 (suppl 8; abstr 03)
19. Conte PF, Bruzzone M, Carnino F, et al: High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14:351-356, 1996
20. Dittrich C, Obermair A, Kurz C, et al: Prospective randomized trial of cisplatin/carboplatin versus conventional cisplatin/cyclophosphamide in epithelial ovarian cancer: First results of the impact of platinum dose-intensity on patient outcome. Proc Am Soc Clin Oncol 15:749, 1996 (abstr)
21. McGuire WP, Hoskins WJ, Bradey MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynaecologic Oncology Group Study. J Clin Oncol 13:1589-1599, 1995
22. Jackobsen A, Bertelsen K, Andersen JE, et al: Dose-effect study of carboplatin in ovarian cancer. A Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198, 1997
23. Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
24. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
25. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
26. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 53:457-481, 1958
28. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
29. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
30. Gore ME, Calvert AH, Smith IE: High dose carboplatin in the treatment of lung cancer and mesothelioma: A phase I dose escalation study. Eur J Cancer Clin Oncol 23:1391-1397, 1987
31. Neijt JP, ten Bokkell Huinink WW, van der Burg MEL, et al: Long-term survival in ovarian cancer. Eur J Cancer 27:1367-1372, 1991
32. Conte PF, Bruzzone M, Carnino F, et al: Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: A randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 9:658-663, 1991
33. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer. A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992
34. Gadducci A, Bruzzone M, Camino F, et al: Twelve-year follow-up of a randomised trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 6:286-290, 1996
35. Omura GA, Blessing JA, Ehrlich CE, et al: A randomised trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57:1725-1730, 1986
36. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. A Gynaecologic Oncology Group Study. J Clin Oncol 7:457-465, 1989
37. Van Howelingen JC, ten Bokkel Huinink WW, van der Burgh MEL, et al: Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 7:769-773, 1989
38. Kaye SB, Lewis C, Paul J, et al: Randomised study of two doses of cisplatin and cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992
39. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
40. Calvert AH, Lind MJ, Ghazal-Aswad S, et al: Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: A phase I dose-intensity study. Semin Oncol 21:1-6, 1994 (suppl 12)
41. Glick J, Kemp G, Rose P, et al: A randomized trial of cyclophosphamide and cisplatin with amifostine in the treatment of advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 13:432, 1994 (abstr)